SCHEMBL6926873

SCHEMBL6926873

CCOP(=O)(OCC)c1cc2cc(S(N)(=O)=O)c(Cl)cc2[nH]c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GRIN1 Q05586 2/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37
GRIN2C Q14957 1/20 0.37
GRIN3A Q8TCU5 1/20 0.37
CA1 P00915 11/20 0.36
CA2 P00918 11/20 0.36
CA12 O43570 10/20 0.36
CA9 Q16790 10/20 0.36
CA3 P07451 8/20 0.36
CA4 P22748 8/20 0.36
CA6 P23280 8/20 0.36
CA5A P35218 8/20 0.36
CA7 P43166 8/20 0.36
CA14 Q9ULX7 8/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6926207 0.89 GRIN1 (0.38) LMNAHSD17B10GRIN1GRIN2DGRIN3B
SCHEMBL7650412 0.86 TSHR (0.37) HSD17B10GRIN1GRIN2DGRIN3BGRIN2A
SCHEMBL7647190 0.86 GRIN1 (0.35) HSD17B10GRIN1GRIN2DGRIN3BGRIN2A
SCHEMBL6929437 0.86 POLB (0.33) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B
SCHEMBL7648020 0.85 GRIN1 (0.35) HSD17B10GRIN1GRIN2DGRIN3BGRIN2A
SCHEMBL7647652 0.85 KDM4E (0.38) HSD17B10GRIN1GRIN2DGRIN3BGRIN2A
SCHEMBL7646322 0.84 GRIN1 (0.34) LMNAGRIN1GRIN2DGRIN3BGRIN2A
SCHEMBL7647829 0.84 POLB (0.37) HSD17B10GRIN1GRIN2DGRIN3BGRIN2A
SCHEMBL7651560 0.84 ALDH1A1 (0.36) USP2HSD17B10GRIN1GRIN2DGRIN3B
SCHEMBL7645904 0.84 GSTO1 (0.34) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596709-B1 For treatment of Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Huntington's chorea LES LABORATOIRES SERVIER (FR) 2003-07-22 US disclosed
US-6518258-B1 6-sulphamoyl -3-quinolyphosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2003-02-11 US disclosed
US-6486143-B2 NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS LES LABORATOIRES SERVIER (FR) 2002-11-26 US disclosed
CN-1320601-A 6-amino or 6-hydrazino-sulfonyl-3-quinolyl phosphonic acid compound, preparing process thereof and pharmaceutical composition contg. same ADIR (FR) 2001-11-07 CN disclosed
US-20010031746-A1 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2001-10-18 US disclosed
CN-1317490-A Novel-6-sulfamine-3-quinolyl phosphonate compounds, its prepn. process and medical compsn. contg. them ADIR (FR) 2001-10-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031746-A1 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds CA6, P2RY6, FPR3 USP2 3788/4885LMNA 4530/4885HSD17B10 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.